Rhinitis, sinusitis, and upper airway disease
Allergic sensitization is age-dependently associated with rhinitis, but less so with asthma

https://doi.org/10.1016/j.jaci.2015.06.015Get rights and content

Background

Epidemiologic data describing the association between allergic sensitization and asthma and allergic rhinitis in adults are scarce.

Objective

To determine the prevalence and impact of specific sensitization to airborne allergens on asthma and allergic rhinitis among adults in relation to age.

Methods

A random population sample (age 21-86 years) was examined with structured interview and analysis of specific IgE to 9 common airborne allergens. Of those invited, 692 (68%) subjects participated in blood sampling. IgE level of 0.35 U/mL or more to the specific allergen was defined as a positive test result.

Results

Allergic sensitization decreased with increasing age, both in the population sample and among subjects with asthma and allergic rhinitis. In a multivariate model, sensitization to animal was significantly positively associated with asthma (odds ratio [OR], 4.80; 95% CI, 2.68-8.60), whereas sensitization to both animal (OR, 3.90; 95% CI, 2.31-6.58) and pollen (OR, 4.25; 95% CI, 2.55-7.06) was significantly associated with allergic rhinitis. The association between allergic sensitization and rhinitis was consistently strongest among the youngest age group, whereas this pattern was not found for asthma. The prevalence of allergic sensitization among patients with asthma decreased by increasing age of asthma onset, 86% with asthma onset at age 6 y or less, 56% at age 7 to 19 years, and 26% with asthma onset at age 20 years or more.

Conclusions

Sensitization to animal was associated with asthma across all age groups; allergic rhinitis was associated with sensitization to both pollen and animal and consistently stronger among younger than among older adults. Early onset of asthma was associated with allergic sensitization among adults with asthma.

Section snippets

Study area

The study was performed within the Obstructive Lung Diseases in Northern Sweden Studies in Norrbotten, the northernmost county of Sweden. The county is sparsely inhabited, with approximately 250,000 inhabitants in an area of 105,000 km2. The climate is subarctic, with cold and long winters and mild summers. The study was approved by the Regional Ethical Review Board at Umeå University, Sweden.

Study population

The study population is presented in Fig E1 in this article's Online Repository at www.jacionline.org.

Prevalence of allergic sensitization

The prevalence of sensitization to any allergen decreased with increasing age: 45% in the age group 21 to 40 years, 30% in the age group 41 to 60 years, and 15% in the age group 61 to 86 years (P < .001) (Table I). A similar trend of a decreasing prevalence by age was observed for the most common sensitizers: dog, cat, timothy, birch, and horse. Sensitization to mite was less common, and only 0.7% were sensitized to mold. No significant differences by sex were observed.

Prevalence of asthma and allergic rhinitis

The prevalence of

Discussion

In this study of adults, a major finding includes a marked decrease in allergic sensitization among subjects with asthma with increasing age of asthma onset. Of those with asthma onset before the age of 6 years, 86% were sensitized in adulthood, whereas only 26% of the subjects with asthma with an adult onset (age ≥20 years) of asthma were sensitized. Furthermore, the PAF of allergic sensitization for asthma was 49% for the age group 22 to 40 years but only 11% for the age group 61 to 86 years.

References (41)

  • C. Miranda et al.

    Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation

    J Allergy Clin Immunol

    (2004)
  • E.P. Ronmark et al.

    Large scale questionnaire survey on respiratory health in Sweden: effects of late- and non-response

    Respir Med

    (2009)
  • B.G. Toelle et al.

    Childhood factors that predict asthma in young adulthood

    Eur Respir J

    (2004)
  • M.R. Sears et al.

    A longitudinal, population-based, cohort study of childhood asthma followed to adulthood

    N Engl J Med

    (2003)
  • A. Bjerg-Backlund et al.

    Asthma during the primary school ages–prevalence, remission and the impact of allergic sensitization

    Allergy

    (2006)
  • Y. Schoefer et al.

    KORA Study Group. Predictivity of allergic sensitization (RAST) for the onset of allergic diseases in adults

    Allergy

    (2008)
  • U. Bodtger et al.

    Rhinitis symptoms and IgE sensitization as risk factors for development of later allergic rhinitis in adults

    Allergy

    (2006)
  • A. Linneberg et al.

    Temporal trends of aeroallergen sensitization over twenty-five years

    Clin Exp Allergy

    (2007)
  • E. Ronmark et al.

    Major increase in allergic sensitization in schoolchildren from 1996 to 2006 in northern Sweden

    J Allergy Clin Immunol

    (2009)
  • K. Blomme et al.

    Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population

    Int Arch Allergy Immunol

    (2013)
  • Cited by (63)

    • Does allergy decrease with age?

      2024, Revue Francaise d'Allergologie
    • Allergic rhinitis in Chinese young adults from the Singapore/Malaysia cross-sectional genetics epidemiology study (SMCGES) cohort: Prevalence, patterns, and epidemiology of allergic rhinitis

      2022, World Allergy Organization Journal
      Citation Excerpt :

      Differences in previous prevalence estimates of AR compared to ours (39.4%) could be attributed to varying sample age groups. Indeed, age influences allergic sensitization, with the highest prevalence in 21–40-year-olds in a population of age range 21–86 years, while rhinitis prevalence increases steadily in children aged 4–18, to a peak at 35.8% in 18-year-olds.30,31 Moreover, Wang et al (2004) estimated the prevalence of rhinitis, which potentially included non-allergic rhinitis cases, resulting in a higher prevalence estimate of AR in 2004.18

    View all citing articles on Scopus

    The studies were funded by the Swedish Heart-Lung Foundation, the Swedish Asthma-Allergy Foundation, the Swedish Research Council, Umeå University, Visare Norr, and Norrbotten County Council. Additional funding was provided by ThermoFisher Scientific, Uppsala, Sweden.

    Disclosure of potential conflict of interest: K. Warm has received research support from the Swedish Heart-Lung Foundation. J. Lötvall has consultant arrangements with Novartis, AstraZeneca, GlaxoSmithKline, Sanofi, and FlagShip ventures; is employed by the University of Gothenburg; has provided expert testimony for Bahr; has received research support from AstraZeneca; has received payment for lectures from AstraZeneca, Novartis, GlaxoSmithKline, and Abdilbrahim; has patents through FlagShip ventures; and has stock/stock options through FlagShip ventures. B. Lundbäck has received research support from AstraZeneca and GlaxoSmithKline; has received payment for lectures from AstraZeneca, GlaxoSmithKline, Novartis, and Takeda; and has participated in advisory board meetings for AstraZeneca, GlaxoSmithKline, and Novartis. E. Rönmark has received research support from the Swedish Heart-Lung Foundation, the Swedish Asthma-Allergy Foundation, the Swedish Research Council, Umeå University, Visare Norr, Norrbotten County Council, and ThermoFisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest.

    View full text